In previous randomized controlled trials (RCTs), SGLT2i has shown a trend towards improving MACE in patients with both ASCVD and HF, suggesting its potential benefit in this population.11–15 Similarly, two major GLP-1 RA trials have indicated potential clinical benefits in this cohort; however, these findings were derived from subgroup analyses with a limited number of patients.16 This evidence concerns the gene GLP1R and atherosclerosis.